RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 208,252 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
Our research colleagues showed up strong this week at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal. More than 25 Alnylam scientists attended to share their work, exchange ideas, and celebrate community members’ achievements as the field grows. Highlights included principal scientist Mikyung Yu, PhD presenting an OTS Paper of the Year detailing progress toward oral delivery of #RNAiTherapeutics in preclinical models, Senior Director of Clinical Research Ishir Bhan presented on an investigational #RNAi therapeutic in development for hypertension and current and former Alnylam colleagues gathering on stage to celebrate former and founding CEO John Maraganore on receiving the OTS Lifetime Achievement Award. Congrats to all! #RNAiTherapeutics #RNAinterference #siRNA
-
U.S. Healthcare Professionals: Learn more about helping your patients manage acute hepatic #porphyria (AHP) in a PeerDirect program led by Dr. Angelika Erwin. Dr. Erwin will discuss symptoms that suggest a diagnosis of AHP, disease management options for this #RareDisease and findings from recent clinical trials of patients living with porphyria. View the session here: https://bit.ly/4e2O9ui
-
We are pleased to announce that we have submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy (ATTR-CM). Read the release: https://bit.ly/47YJckw #cardiology #RNAiTherapeutics #RNAinterference
-
Congratulations to our former and founding CEO John Maraganore on being awarded the Lifetime Achievement Award by the Oligonucleotide Therapeutics Society for his incredible contributions to the advancement of #oligonucleotide therapeutics and pioneering leadership in the #RNAiRevolution! #ots24 #RNAi #RNAiTherapeutics
Congratulations to John Maraganore, Ph.D. for winning the OTS Lifetime Achievement Award! #ots24 #ots #oligomeeting #oligotherapeutics #biotech #biotechnology #science #research John Maraganore
-
We extend our heartfelt congratulations to Victor Ambros and Gary Ruvkun of UMass Chan Medical School and Harvard Medical School respectively on receiving this year's #NobelPrize in Physiology or Medicine for the discovery of microRNAs. This breakthrough research helped pave the way for the incredible era of RNA-based medicines we're living in and are proud to be part of! #RNA #RNAi #RNA #science
-
Happy #ManufacturingDay! We’d like to celebrate and thank our dedicated manufacturing team whose passion for innovation and unwavering commitment to excellence bring our #RNAi therapeutics to patients around the world. Your teamwork and relentless drive to deliver on our mission for patients inspires us every day! #RNAiTherapeutics #Biotech #Biopharma #Manufacturing
-
Healthcare Professionals: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage and respiratory paralysis. Learn how timely diagnosis and management can help avoid potentially devastating outcomes: https://bit.ly/4cNnDEv
-
Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice.
-
Yesterday, we presented additional data from the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAiTherapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy (ATTR-CM) during the Heart Failure Society of America Annual Scientific Meeting 2024 (#HFSA24). See the data: https://bit.ly/4gDqJOm #cardiology #RNAi #RNAinterference
Similar pages
Browse jobs
Stock
ALNY
NASDAQ
20 minutes delay
$284.32
5.7 (2.046%)
- Open
- 278.8
- Low
- 278.26
- High
- 286.02
Data from Refinitiv
See more info on